Introduction
Hypoglycemia is a rare but potentially life-threatening presentation of soft tissue tumors the etiology of hypoglycemia may be difficult to diagnose. Retroperitoneal sarcomas have rarely been reported to secrete insulin-growth factor II (IGF-II) which can lead to low blood glucose levels. IGF-II-secreting sarcomas represent an extremely rare subset of soft tissue tumors, and there is no consensus on the ideal management of the hypoglycemia associated with this tumor-type. Here we present a case report of hypoglycemia with a large retroperitoneal mass and review of the literature.
Presentation of the case
A 38-year-old diabetic man presented with increasing episodes of hypoglycemia over the previous 8 months. As a consequent, his insulin had been discontinued 5 months prior, despite a long history of insulin-dependent diabetes. He also complained of increasing abdominal girth over the previous several months and 15 pound weight loss. A varicocele was discovered by ultrasound after complaints of worsening right testicular pain. Biochemical work-up revealed blood glucose level was very low at 32 mg/DL. Total and free insulin levels were <1.2 and <1.5 IU/mL (normal: 0-22 IU/mL), respectively. Elevated Insulin-Like Growth Factor (IGF)-II level was 944 ng/mL (normal: 288-736 ng/mL). IGF-1 levels were reduced and C-peptide levels were undetectable (normal: 1.1-4.4 nL/mL). Computer tomography (CT) of abdomen demonstrated a large right retroperitoneal tumor involving the right kidney and displacing the IVC and liver (Fig. 1A) .
The patient was admitted preoperatively for intravenous dextrose while unable to eat prior to surgery. He underwent an en block tumor resection via a chevron incision secondary to the size of the mass. After the celiotomy, a large mass arising from the retroperitoneum was encountered occupying the majority of the right hemi-abdomen ( Fig. 1B ). During tumor extirpation, a plane could not be developed between the mass and right kidney. Therefore, a right nephrectomy was included in the en block resection. The tumor weighed 3.25 kg and measured 19.5 cm × 17.2 cm × 13.5 cm ( Fig. 1B , inset). Pathological examination using stains, immunohistochemistry, electron microscopy and molecular and cytogenetic studies showed a primitive, undifferentiated mesenchymal tumor (sarcoma).
After surgery, the patient was taken to the intensive care unit for blood sugar monitoring. The expected half-lives of free IGF-II and carrier protein-bound IGF-II in a healthy male are 10-12 min and 12-15 h, respectively. 1 However, immediately postoperatively, the patient's glucose levels elevated to the 200s mg/dL. He was started on an insulin drip with intravenous dextrose and then was transitioned to subcutaneous insulin with resumption of a diet. He was discharged home on postoperative day 6 with a serum glucose range 90-237 mg/dL. Within one month, the patient's IGF-II level returned to normal (317 ng/mL) with a serum glucose of 170 mg/dL. One-year post-operatively, he has returned to normal activities. He has had no further episodes of hypoglycemia, and his serum glucose level was elevated at 237 mg/dL, for which he is being evaluated for an insulin pump.
Discussion and literature review
Patients with non-islet cell tumors secreting IGF-II can have hypoglycemia because of increased glucose uptake into peripheral insulin target tissues and suppressed hepatic glucose production. 2 Therefore, tumor-induced hypoglycemia should be considered in a patient with low blood glucose, low C-peptide, low fasting insulin levels and weight loss. [3] [4] [5] [6] [7] [8] Management of hypoglycemia in a patient with an IGF-IIsecreting tumor remains under some deliberation. As shown in Table 1 , Rose et al. reported on a 54 year old woman with an IGF-II secreting abdominal mesenchymal tumor leading to malignant hypoglycemia. 4 Despite intratumoral alcohol injections and surgical debulking, this patient died 24 h after surgery due to persistent hypoglycemia. Teale et al. reported on 8 cases of hypoglycemia due to IGF-II-secreting tumors. 3 They concluded that chronic steroid therapy may successfully treat hypoglycemia in some patients and complete surgical resection is recommended when possible. De Groot et al. reported on two adult patients with IGF-II-secreting tumors: one with a "solid fibrous tumor" of the kidney and another with a metastatic hemangiopericytoma. 6 The first patient's hypoglycemia immediately resolved after resection of the kidney mass. The second patient harbored several unresectable masses. With chronic corticosteroid therapy and chemotherapy, this patient remained free of hypoglycemic events for more than a year. 6 Bourcigaux et al. reported resolution of hypoglycemia with combined chronic steroids and recombinant human growth hormone. 8 Chan et al. reported resolution of hypoglycemia after steroids and complete resection. 7 Dutta et al. reported 5 IGF-II-secreting tumors including a retroperitoneal sarcoma, hemangiopericytoma, adrenocortical carcinoma, pleural mesothelioma and a retroperitoneal leiomyosarcoma. 5 Four patients underwent complete resections and all remained free from hypoglycemic events at follow up (6 months-6 years). One patient showed stable tumor disease while the other four showed no recurrence.
Conclusion
This case and review of the literature show that the most effective treatment for hypoglycemia due to an IGF-II-secreting sarcoma is complete surgical resection. [4] [5] [6] If the tumor is not resectable and diet with glucose supplementation do not address the hypoglycemia, glucocorticoids and growth hormone may help in mildly symptomatic patients. [4] [5] [6] Other treatments such as chemotherapy, radiotherapy, tumor embolization and alcohol injections into the tumor have been used but seem to have little effect on hypoglycemia induced by IGF-II secreting soft tissue masses. [4] [5] [6] In summary, we report a case of a 38-year-old who presents with hypoglycemia due to an IGF-II-secreting retroperitoneal undifferentiated mesenchymal tumor that was successfully treated by surgical resection.
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